Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s Inclisiran Unscathed As Arrowhead Falls Short

But NASH Candidate Generates Interest

Executive Summary

Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.

You may also be interested in...



J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn

Investment from Janssen helps to validate the platform developed by the San Diego-based company.

COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen

Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.

Moderna Not Immune To COVID-19 Effects On Trials

Company suspends enrolment to trials as coronavirus travel restrictions bite.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141617

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel